- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- Charles River to Perform Plasmid Production for Ship of Theseus
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
- Charles River Laboratories Publishes 2023 Corporate Citizenship Report
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
More ▼
Key statistics
As of last trade Charles River Laboratories International Inc (CRL:NYQ) traded at 237.18, -13.75% below its 52-week high of 275.00, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 236.90 |
---|---|
High | 238.23 |
Low | 235.39 |
Bid | 236.99 |
Offer | 237.31 |
Previous close | 235.27 |
Average volume | 495.88k |
---|---|
Shares outstanding | 51.51m |
Free float | 50.58m |
P/E (TTM) | 25.49 |
Market cap | 12.12bn USD |
EPS (TTM) | 9.23 USD |
Data delayed at least 15 minutes, as of May 07 2024 18:17 BST.
More ▼